SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,175.00
-15.00 (-0.47%)
Jun 19, 2025, 2:40 PM KST
-15.33%
Market Cap 440.63B
Revenue (ttm) 4.78B
Net Income (ttm) -26.43B
Shares Out 138.13M
EPS (ttm) -204.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 378,687
Average Volume 647,497
Open 3,275.00
Previous Close 3,190.00
Day's Range 3,135.00 - 3,275.00
52-Week Range 1,873.00 - 4,700.00
Beta 0.10
RSI 48.65
Earnings Date Aug 12, 2025

About SillaJen

SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of solid tumors and induction of cancer specific antibodies. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 37
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.

Financial Statements

News

There is no news available yet.